25 XP   0   0   10

FibroGen Inc
Buy, Hold or Sell?

Let's analyse Fibrogen together

PenkeI guess you are interested in FibroGen Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of FibroGen Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about FibroGen Inc

I send you an email if I find something interesting about FibroGen Inc.

Quick analysis of Fibrogen (30 sec.)










What can you expect buying and holding a share of Fibrogen? (30 sec.)

How much money do you get?

How much money do you get?
$0.02
When do you have the money?
1 year
How often do you get paid?
7.5%

What is your share worth?

Current worth
$-1.64
Expected worth in 1 year
$-3.27
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-1.60
Return On Investment
-157.3%

For what price can you sell your share?

Current Price per Share
$1.02
Expected price per share
$0.91 - $2.8
How sure are you?
50%

1. Valuation of Fibrogen (5 min.)




Live pricePrice per Share (EOD)

$1.02

Intrinsic Value Per Share

$-19.83 - $-5.35

Total Value Per Share

$-21.47 - $-6.99

2. Growth of Fibrogen (5 min.)




Is Fibrogen growing?

Current yearPrevious yearGrowGrow %
How rich?-$162.1m$86.6m-$178.2m-194.5%

How much money is Fibrogen making?

Current yearPrevious yearGrowGrow %
Making money-$71.2m-$73.8m$2.5m3.6%
Net Profit Margin-194.5%-282.1%--

How much money comes from the company's main activities?

3. Financial Health of Fibrogen (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#1000 / 1010

Most Revenue
#177 / 1010

Most Profit
#933 / 1010

Most Efficient
#622 / 1010

What can you expect buying and holding a share of Fibrogen? (5 min.)

Welcome investor! Fibrogen's management wants to use your money to grow the business. In return you get a share of Fibrogen.

What can you expect buying and holding a share of Fibrogen?

First you should know what it really means to hold a share of Fibrogen. And how you can make/lose money.

Speculation

The Price per Share of Fibrogen is $1.02. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Fibrogen.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Fibrogen, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-1.64. Based on the TTM, the Book Value Change Per Share is $-0.41 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.58 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.01 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Fibrogen.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.57-55.8%-0.72-70.5%-0.74-72.9%-0.57-56.3%-0.40-39.0%
Usd Book Value Change Per Share-0.48-46.6%-0.41-39.9%-0.58-57.2%-0.35-34.3%-0.07-6.7%
Usd Dividend Per Share0.022.2%0.010.6%0.000.4%0.000.2%0.000.1%
Usd Total Gains Per Share-0.45-44.4%-0.40-39.3%-0.58-56.8%-0.35-34.1%-0.07-6.6%
Usd Price Per Share0.89-5.78-12.90-24.66-27.04-
Price to Earnings Ratio-0.39--1.87--4.44--4.82--9.62-
Price-to-Total Gains Ratio-1.96--19.81--23.22--41.55--98.68-
Price to Book Ratio-0.54--17.38--256.57--50.18--20.36-
Price-to-Total Gains Ratio-1.96--19.81--23.22--41.55--98.68-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.02
Number of shares980
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.00
Usd Book Value Change Per Share-0.41-0.35
Usd Total Gains Per Share-0.40-0.35
Gains per Quarter (980 shares)-393.07-340.62
Gains per Year (980 shares)-1,572.27-1,362.49
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
122-1595-15828-1371-1372
245-3189-315416-2741-2734
367-4784-472624-4112-4096
489-6379-629832-5482-5458
5112-7973-787040-6853-6820
6134-9568-944248-8223-8182
7157-11162-1101456-9594-9544
8179-12757-1258664-10964-10906
9201-14352-1415873-12335-12268
10224-15946-1573081-13706-13630

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%7.033.00.017.5%8.034.01.018.6%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%10.029.01.025.0%11.030.02.025.6%
Dividend per Share1.00.03.025.0%3.00.09.025.0%3.00.017.015.0%3.00.037.07.5%3.00.040.07.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%10.029.01.025.0%11.030.02.025.6%

Fundamentals of Fibrogen

About FibroGen Inc

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Fundamental data was last updated by Penke on 2024-04-11 07:51:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of FibroGen Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Fibrogen earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Fibrogen to the Biotechnology industry mean.
  • A Net Profit Margin of -207.2% means that $-2.07 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of FibroGen Inc:

  • The MRQ is -207.2%. The company is making a huge loss. -2
  • The TTM is -194.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-207.2%TTM-194.5%-12.7%
TTM-194.5%YOY-282.1%+87.6%
TTM-194.5%5Y-273.3%+78.8%
5Y-273.3%10Y-194.6%-78.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-207.2%-207.2%0.0%
TTM-194.5%-216.8%+22.3%
YOY-282.1%-282.3%+0.2%
5Y-273.3%-436.8%+163.5%
10Y-194.6%-597.3%+402.7%
1.1.2. Return on Assets

Shows how efficient Fibrogen is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Fibrogen to the Biotechnology industry mean.
  • -13.3% Return on Assets means that Fibrogen generated $-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of FibroGen Inc:

  • The MRQ is -13.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -14.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.3%TTM-14.6%+1.3%
TTM-14.6%YOY-11.3%-3.3%
TTM-14.6%5Y-8.7%-5.9%
5Y-8.7%10Y-6.3%-2.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.3%-13.3%+0.0%
TTM-14.6%-12.8%-1.8%
YOY-11.3%-11.6%+0.3%
5Y-8.7%-13.8%+5.1%
10Y-6.3%-15.6%+9.3%
1.1.3. Return on Equity

Shows how efficient Fibrogen is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Fibrogen to the Biotechnology industry mean.
  • 0.0% Return on Equity means Fibrogen generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of FibroGen Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-115.2%+115.2%
TTM-5Y-32.2%+32.2%
5Y-32.2%10Y-21.4%-10.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM--16.1%+16.1%
YOY-115.2%-14.9%-100.3%
5Y-32.2%-19.3%-12.9%
10Y-21.4%-20.1%-1.3%

1.2. Operating Efficiency of FibroGen Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Fibrogen is operating .

  • Measures how much profit Fibrogen makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Fibrogen to the Biotechnology industry mean.
  • An Operating Margin of -199.7% means the company generated $-2.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of FibroGen Inc:

  • The MRQ is -199.7%. The company is operating very inefficient. -2
  • The TTM is -182.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-199.7%TTM-182.7%-17.0%
TTM-182.7%YOY-288.4%+105.7%
TTM-182.7%5Y-276.4%+93.7%
5Y-276.4%10Y-191.5%-85.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-199.7%-298.0%+98.3%
TTM-182.7%-238.5%+55.8%
YOY-288.4%-288.4%0.0%
5Y-276.4%-486.2%+209.8%
10Y-191.5%-628.4%+436.9%
1.2.2. Operating Ratio

Measures how efficient Fibrogen is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.00 means that the operating costs are $3.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of FibroGen Inc:

  • The MRQ is 2.997. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.839. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.997TTM2.839+0.158
TTM2.839YOY3.884-1.045
TTM2.8395Y3.878-1.039
5Y3.87810Y3.980-0.102
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9973.235-0.238
TTM2.8393.310-0.471
YOY3.8843.838+0.046
5Y3.8785.679-1.801
10Y3.9807.823-3.843

1.3. Liquidity of FibroGen Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Fibrogen is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.52 means the company has $1.52 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of FibroGen Inc:

  • The MRQ is 1.523. The company is able to pay all its short-term debts. +1
  • The TTM is 1.768. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.523TTM1.768-0.245
TTM1.768YOY1.976-0.208
TTM1.7685Y4.454-2.686
5Y4.45410Y4.792-0.338
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5233.863-2.340
TTM1.7684.169-2.401
YOY1.9765.337-3.361
5Y4.4546.122-1.668
10Y4.7926.434-1.642
1.3.2. Quick Ratio

Measures if Fibrogen is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Fibrogen to the Biotechnology industry mean.
  • A Quick Ratio of 1.83 means the company can pay off $1.83 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of FibroGen Inc:

  • The MRQ is 1.831. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.184. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.831TTM2.184-0.353
TTM2.184YOY2.786-0.602
TTM2.1845Y6.062-3.878
5Y6.06210Y5.994+0.068
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8313.504-1.673
TTM2.1843.991-1.807
YOY2.7865.371-2.585
5Y6.0626.088-0.026
10Y5.9946.395-0.401

1.4. Solvency of FibroGen Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Fibrogen assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Fibrogen to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.38 means that Fibrogen assets are financed with 138.3% credit (debt) and the remaining percentage (100% - 138.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of FibroGen Inc:

  • The MRQ is 1.383. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.201. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.383TTM1.201+0.182
TTM1.201YOY0.877+0.324
TTM1.2015Y0.696+0.505
5Y0.69610Y0.611+0.085
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3830.339+1.044
TTM1.2010.337+0.864
YOY0.8770.271+0.606
5Y0.6960.368+0.328
10Y0.6110.388+0.223
1.4.2. Debt to Equity Ratio

Measures if Fibrogen is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Fibrogen to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of FibroGen Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY7.601-7.601
TTM-5Y2.161-2.161
5Y2.16110Y1.771+0.390
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.392-0.392
TTM-0.403-0.403
YOY7.6010.335+7.266
5Y2.1610.427+1.734
10Y1.7710.461+1.310

2. Market Valuation of FibroGen Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Fibrogen generates.

  • Above 15 is considered overpriced but always compare Fibrogen to the Biotechnology industry mean.
  • A PE ratio of -0.39 means the investor is paying $-0.39 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of FibroGen Inc:

  • The EOD is -0.448. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.389. Based on the earnings, the company is expensive. -2
  • The TTM is -1.873. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.448MRQ-0.389-0.059
MRQ-0.389TTM-1.873+1.484
TTM-1.873YOY-4.442+2.569
TTM-1.8735Y-4.819+2.946
5Y-4.81910Y-9.615+4.796
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.448-2.300+1.852
MRQ-0.389-2.656+2.267
TTM-1.873-2.718+0.845
YOY-4.442-4.145-0.297
5Y-4.819-6.258+1.439
10Y-9.615-6.315-3.300
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of FibroGen Inc:

  • The EOD is -1.356. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.178. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.634. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.356MRQ-1.178-0.178
MRQ-1.178TTM-1.634+0.455
TTM-1.634YOY-6.958+5.324
TTM-1.6345Y-38.752+37.118
5Y-38.75210Y-36.508-2.244
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.356-2.974+1.618
MRQ-1.178-3.306+2.128
TTM-1.634-3.508+1.874
YOY-6.958-5.613-1.345
5Y-38.752-8.378-30.374
10Y-36.508-8.873-27.635
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Fibrogen is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.54 means the investor is paying $-0.54 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of FibroGen Inc:

  • The EOD is -0.621. Based on the equity, the company is expensive. -2
  • The MRQ is -0.540. Based on the equity, the company is expensive. -2
  • The TTM is -17.377. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.621MRQ-0.540-0.081
MRQ-0.540TTM-17.377+16.837
TTM-17.377YOY-256.566+239.189
TTM-17.3775Y-50.176+32.799
5Y-50.17610Y-20.363-29.813
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.6211.914-2.535
MRQ-0.5402.116-2.656
TTM-17.3772.097-19.474
YOY-256.5662.881-259.447
5Y-50.1763.550-53.726
10Y-20.3633.936-24.299
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of FibroGen Inc.

3.1. Institutions holding FibroGen Inc

Institutions are holding 71.449% of the shares of FibroGen Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31PRIMECAP Management Company14.6520.010214471928-253040-1.7184
2023-12-31Armistice Capital, LLC9.88550.11819764000187200023.7202
2023-12-31BlackRock Inc7.29490.00027205300-830389-10.3338
2023-12-31Vanguard Group Inc7.13180.00017044149-2016794-22.2581
2023-09-30Jacobs Levy Equity Management, Inc.2.58890.013125571281559903156.4244
2023-12-31Acadian Asset Management LLC2.49960.0085246892885383452.8659
2023-12-31Assenagon Asset Management SA2.25460.0052222685700
2023-12-31Two Sigma Investments LLC2.12740.0043210128323808112.7781
2023-12-31Geode Capital Management, LLC2.04340.000220182811333297.0733
2023-12-31State Street Corporation1.83320.000118106801048096.144
2023-12-31Two Sigma Advisers, LLC1.82280.0037180040016770010.2713
2023-09-30Citadel Advisors Llc1.2660.00021250444962473334.2257
2023-12-31AQR Capital Management LLC1.17980.0019116526130147834.9021
2023-12-31Morgan Stanley - Brokerage Accounts0.82670.0001816525-582475-41.6351
2023-12-31Northern Trust Corp0.78710.0001777443372655.0346
2023-12-31Pennant Investors LP0.7780.14877684007684000
2023-09-30D. E. Shaw & Co LP0.73350.00077244426906122041.4189
2023-12-31683 Capital Management LLC0.7090.05087002547002540
2023-12-31Renaissance Technologies Corp0.69190.00096834126274121120.3786
2023-12-31Millennium Management LLC0.6150.0002607409-1658648-73.1953
Total 61.72110.367360962524+3676204+6.0%

3.2. Funds holding FibroGen Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Capital Opportunity Inv5.48580.0229541842100
2023-12-31PRIMECAP Odyssey Aggressive Growth4.29370.0523424095100
2024-02-29Vanguard Total Stock Mkt Idx Inv2.94860.0003291235000
2023-12-31PRIMECAP Odyssey Growth2.45340.03142423300-22810-0.9325
2024-03-28iShares Russell 2000 ETF2.3230.0082229447611070.0483
2023-12-31Vanguard Strategic Small-Cap Equity Inv1.61510.0949159523700
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.33780.002213213181063638.7545
2024-01-31Fidelity Small Cap Index0.94480.0072933235366374.0862
2024-03-28iShares Russell 2000 Value ETF0.91510.0169903883475465.5523
2023-12-31Vanguard US Opportunities Ins USD Acc0.62270.043561508100
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.55590.002354908389001.6476
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.38830.009338353500
2024-02-29Fidelity Extended Market Index0.37310.0016368537-147688-28.6092
2024-02-29Vanguard Russell 2000 ETF0.33140.0059327294263448.7536
2024-02-29Vanguard Health Care ETF0.33110.0027327013246588.1553
2023-12-31NT R2000 Value Index Fund - NL0.31250.00723086863428912.4961
2023-12-31NT R2000 Index Fund - NL0.31030.00383064983440312.6437
2024-02-29Multi-Manager Small Cap Eq Strat Inst0.28750.031928393200
2023-12-31Vanguard Explorer Inv0.24990.00124679500
2023-12-31NT R2000 Index Fund - DC - NL - 20.24440.00382413702626612.2108
Total 26.32440.349326000995+176015+0.7%

3.3. Insider Transactions

Insiders are holding 6.368% of the shares of FibroGen Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-07Thane WettigBUY500001.91
2023-09-01Jeffrey William HendersonSELL20001.03
2023-08-04Jeffrey William HendersonSELL20001.91
2023-07-11Jeffrey William HendersonSELL20002.69
2023-07-07Enrique A ConternoSELL18802.8
2023-06-23Thane WettigSELL79116.53
2023-06-13Christine ChungSELL625017.6
2023-06-09Benjamin CravattSELL394417.17
2023-06-07Christine ChungSELL363317.04
2023-06-07Enrique A ConternoSELL889717.04
2023-06-07James A SchoeneckSELL710018.03
2023-06-07Juan GrahamSELL178516.99
2023-06-07Mark EisnerSELL204217.04
2023-06-07Thane WettigSELL175817.04
2023-06-02Mark EisnerSELL109018.83
2023-04-10Enrique A ConternoSELL186919.52

4. Summary

4.1. Key Performance Indicators

The key performance indicators of FibroGen Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.476-0.407-15%-0.584+23%-0.350-27%-0.068-86%
Book Value Per Share---1.642-0.928-43%0.877-287%2.701-161%2.843-158%
Current Ratio--1.5231.768-14%1.976-23%4.454-66%4.792-68%
Debt To Asset Ratio--1.3831.201+15%0.877+58%0.696+99%0.611+127%
Debt To Equity Ratio----0%7.601-100%2.161-100%1.771-100%
Dividend Per Share--0.0230.006+300%0.005+399%0.002+1011%0.001+2121%
Eps---0.569-0.719+26%-0.743+31%-0.574+1%-0.397-30%
Free Cash Flow Per Share---0.188-0.804+327%-0.467+149%-0.315+67%-0.198+5%
Free Cash Flow To Equity Per Share---0.191-0.493+159%-0.349+83%-0.225+18%0.025-849%
Gross Profit Margin--1.0001.0000%1.0000%1.055-5%1.027-3%
Intrinsic Value_10Y_max---5.350--------
Intrinsic Value_10Y_min---19.828--------
Intrinsic Value_1Y_max---0.755--------
Intrinsic Value_1Y_min---2.073--------
Intrinsic Value_3Y_max---2.102--------
Intrinsic Value_3Y_min---6.190--------
Intrinsic Value_5Y_max---3.247--------
Intrinsic Value_5Y_min---10.235--------
Market Cap100746624.000+13%87540914.560570630853.760-85%1274395408.000-93%2436039540.352-96%2670919429.376-97%
Net Profit Margin---2.072-1.945-6%-2.821+36%-2.733+32%-1.946-6%
Operating Margin---1.997-1.827-8%-2.884+44%-2.764+38%-1.915-4%
Operating Ratio--2.9972.839+6%3.884-23%3.878-23%3.980-25%
Pb Ratio-0.621-15%-0.540-17.377+3120%-256.566+47437%-50.176+9197%-20.363+3673%
Pe Ratio-0.448-15%-0.389-1.873+381%-4.442+1041%-4.819+1138%-9.615+2371%
Price Per Share1.020+13%0.8865.777-85%12.903-93%24.663-96%27.041-97%
Price To Free Cash Flow Ratio-1.356-15%-1.178-1.634+39%-6.958+490%-38.752+3189%-36.508+2998%
Price To Total Gains Ratio-2.252-15%-1.957-19.812+913%-23.216+1087%-41.545+2023%-98.680+4944%
Quick Ratio--1.8312.184-16%2.786-34%6.062-70%5.994-69%
Return On Assets---0.133-0.146+10%-0.113-15%-0.087-35%-0.063-52%
Return On Equity----0%-1.1520%-0.3220%-0.2140%
Total Gains Per Share---0.453-0.401-11%-0.579+28%-0.348-23%-0.067-85%
Usd Book Value---162199000.000-91648250.000-43%86638750.000-287%266766700.000-161%280770200.000-158%
Usd Book Value Change Per Share---0.476-0.407-15%-0.584+23%-0.350-27%-0.068-86%
Usd Book Value Per Share---1.642-0.928-43%0.877-287%2.701-161%2.843-158%
Usd Dividend Per Share--0.0230.006+300%0.005+399%0.002+1011%0.001+2121%
Usd Eps---0.569-0.719+26%-0.743+31%-0.574+1%-0.397-30%
Usd Free Cash Flow---18572000.000-79385000.000+327%-46168500.000+149%-31074550.000+67%-19526600.000+5%
Usd Free Cash Flow Per Share---0.188-0.804+327%-0.467+149%-0.315+67%-0.198+5%
Usd Free Cash Flow To Equity Per Share---0.191-0.493+159%-0.349+83%-0.225+18%0.025-849%
Usd Market Cap100746624.000+13%87540914.560570630853.760-85%1274395408.000-93%2436039540.352-96%2670919429.376-97%
Usd Price Per Share1.020+13%0.8865.777-85%12.903-93%24.663-96%27.041-97%
Usd Profit---56232000.000-71257000.000+27%-73806500.000+31%-56826950.000+1%-38903150.000-31%
Usd Revenue--27138000.00036938000.000-27%35183750.000-23%47834600.000-43%44833100.000-39%
Usd Total Gains Per Share---0.453-0.401-11%-0.579+28%-0.348-23%-0.067-85%
 EOD+6 -2MRQTTM+13 -20YOY+20 -145Y+16 -1910Y+9 -26

4.2. Fundamental Score

Let's check the fundamental score of FibroGen Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.448
Price to Book Ratio (EOD)Between0-1-0.621
Net Profit Margin (MRQ)Greater than0-2.072
Operating Margin (MRQ)Greater than0-1.997
Quick Ratio (MRQ)Greater than11.831
Current Ratio (MRQ)Greater than11.523
Debt to Asset Ratio (MRQ)Less than11.383
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.133
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of FibroGen Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5028.381
Ma 20Greater thanMa 501.459
Ma 50Greater thanMa 1001.824
Ma 100Greater thanMa 2001.456
OpenGreater thanClose0.950
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets423,529
Total Liabilities585,728
Total Stockholder Equity-204,166
 As reported
Total Liabilities 585,728
Total Stockholder Equity+ -204,166
Total Assets = 423,529

Assets

Total Assets423,529
Total Current Assets331,559
Long-term Assets91,970
Total Current Assets
Cash And Cash Equivalents 113,688
Short-term Investments 121,898
Net Receivables 41,053
Inventory 41,565
Other Current Assets 13,355
Total Current Assets  (as reported)331,559
Total Current Assets  (calculated)331,559
+/-0
Long-term Assets
Property Plant Equipment 81,372
Long Term Investments 5,290
Long-term Assets Other 3,650
Long-term Assets  (as reported)91,970
Long-term Assets  (calculated)90,312
+/- 1,658

Liabilities & Shareholders' Equity

Total Current Liabilities217,668
Long-term Liabilities368,060
Total Stockholder Equity-204,166
Total Current Liabilities
Short-term Debt 14,117
Accounts payable 17,960
Other Current Liabilities 172,851
Total Current Liabilities  (as reported)217,668
Total Current Liabilities  (calculated)204,928
+/- 12,740
Long-term Liabilities
Long term Debt 71,934
Capital Lease Obligations 80,614
Long-term Liabilities Other 72,034
Long-term Liabilities  (as reported)368,060
Long-term Liabilities  (calculated)224,582
+/- 143,478
Total Stockholder Equity
Common Stock988
Retained Earnings -1,841,920
Accumulated Other Comprehensive Income -6,875
Other Stockholders Equity 1,643,641
Total Stockholder Equity (as reported)-204,166
Total Stockholder Equity (calculated)-204,166
+/-0
Other
Capital Stock988
Cash and Short Term Investments 235,586
Common Stock Shares Outstanding 98,496
Current Deferred Revenue12,740
Liabilities and Stockholders Equity 423,529
Net Debt 56,767
Net Invested Capital -132,232
Net Working Capital 113,891
Property Plant and Equipment Gross 253,066
Short Long Term Debt Total 170,455



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302012-12-31
> Total Assets 
265,588
0
296,952
0
372,657
344,383
483,528
435,540
541,395
499,247
470,574
442,535
499,129
486,213
469,552
441,756
542,638
894,892
898,650
867,611
869,919
855,641
880,598
812,397
915,066
893,964
857,397
824,377
807,683
812,015
826,840
787,301
808,618
850,513
773,821
745,934
686,789
608,837
610,087
538,544
515,127
460,426
423,529
423,529460,426515,127538,544610,087608,837686,789745,934773,821850,513808,618787,301826,840812,015807,683824,377857,397893,964915,066812,397880,598855,641869,919867,611898,650894,892542,638441,756469,552486,213499,129442,535470,574499,247541,395435,540483,528344,383372,6570296,9520265,588
   > Total Current Assets 
0
0
143,643
0
220,630
199,828
198,238
155,400
263,579
232,573
200,564
184,001
252,309
253,462
266,516
256,581
371,344
741,456
748,970
717,163
720,083
678,783
690,015
579,000
805,791
786,480
702,490
736,405
727,168
737,484
755,110
621,694
564,466
573,399
474,059
524,415
520,643
474,224
492,826
430,549
411,357
364,108
331,559
331,559364,108411,357430,549492,826474,224520,643524,415474,059573,399564,466621,694755,110737,484727,168736,405702,490786,480805,791579,000690,015678,783720,083717,163748,970741,456371,344256,581266,516253,462252,309184,001200,564232,573263,579155,400198,238199,828220,6300143,64300
       Cash And Cash Equivalents 
38,872
0
76,332
0
182,662
153,889
165,455
128,369
236,536
208,650
153,324
140,959
190,411
198,283
173,782
170,598
290,277
651,373
673,658
659,007
643,803
566,722
89,258
81,673
74,587
196,592
126,266
121,560
429,269
532,468
678,393
433,508
353,361
274,527
171,223
185,896
167,758
155,960
155,700
188,550
152,585
120,914
113,688
113,688120,914152,585188,550155,700155,960167,758185,896171,223274,527353,361433,508678,393532,468429,269121,560126,266196,59274,58781,67389,258566,722643,803659,007673,658651,373290,277170,598173,782198,283190,411140,959153,324208,650236,536128,369165,455153,889182,662076,332038,872
       Short-term Investments 
1,017
0
46,477
0
19,427
21,612
14,364
14,322
12,129
12,873
27,847
32,454
40,105
43,522
79,397
72,824
69,121
78,599
62,060
44,761
28,094
86,009
532,144
483,726
586,174
432,040
407,491
413,869
256,317
155,398
8,144
110,724
153,851
211,875
233,967
242,179
270,375
252,560
266,308
167,399
183,131
130,426
121,898
121,898130,426183,131167,399266,308252,560270,375242,179233,967211,875153,851110,7248,144155,398256,317413,869407,491432,040586,174483,726532,14486,00928,09444,76162,06078,59969,12172,82479,39743,52240,10532,45427,84712,87312,12914,32214,36421,61219,427046,47701,017
       Net Receivables 
0
0
17,495
0
16,166
21,425
13,453
6,963
12,183
7,373
15,405
5,937
18,088
7,692
10,448
7,248
8,933
8,628
8,452
9,975
30,189
23,187
63,684
6,023
6,453
19,225
28,455
58,540
26,519
26,252
41,883
44,573
24,266
43,994
17,401
43,883
33,573
15,328
16,299
17,654
25,599
31,694
41,053
41,05331,69425,59917,65416,29915,32833,57343,88317,40143,99424,26644,57341,88326,25226,51958,54028,45519,2256,4536,02363,68423,18730,1899,9758,4528,6288,9337,24810,4487,69218,0885,93715,4057,37312,1836,96313,45321,42516,166017,49500
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,981
4,908
6,887
8,408
8,582
11,803
16,530
20,764
24,530
29,315
31,015
43,067
40,899
39,950
40,436
42,456
41,179
40,696
41,565
41,56540,69641,17942,45640,43639,95040,89943,06731,01529,31524,53020,76416,53011,8038,5828,4086,8874,9081,981000000000000000000000000
   > Long-term Assets 
0
0
153,309
0
152,027
144,555
285,290
280,140
277,816
266,674
270,010
258,534
246,820
232,751
203,036
185,175
171,294
153,436
149,680
150,448
149,836
176,858
190,583
233,397
109,275
107,484
154,907
87,972
80,515
74,531
71,730
165,607
244,152
277,114
299,762
221,519
166,146
134,613
117,261
107,995
103,770
96,318
91,970
91,97096,318103,770107,995117,261134,613166,146221,519299,762277,114244,152165,60771,73074,53180,51587,972154,907107,484109,275233,397190,583176,858149,836150,448149,680153,436171,294185,175203,036232,751246,820258,534270,010266,674277,816280,140285,290144,555152,0270153,30900
       Property Plant Equipment 
123,664
0
129,898
0
133,337
132,553
132,171
131,660
130,451
129,607
129,020
127,613
126,264
124,774
123,657
122,818
122,591
126,643
129,476
129,880
128,829
127,908
127,198
92,857
89,401
85,272
82,345
77,075
71,352
68,181
63,253
58,244
128,622
123,878
120,150
114,871
109,159
105,190
100,498
95,367
91,233
85,760
81,372
81,37285,76091,23395,367100,498105,190109,159114,871120,150123,878128,62258,24463,25368,18171,35277,07582,34585,27289,40192,857127,198127,908128,829129,880129,476126,643122,591122,818123,657124,774126,264127,613129,020129,607130,451131,660132,171132,553133,3370129,8980123,664
       Long Term Investments 
0
0
0
0
0
0
144,269
139,518
138,310
127,974
131,720
122,009
111,540
98,730
71,010
53,155
39,204
16,767
10,506
10,506
10,587
40,602
55,820
132,203
10,915
10,999
61,118
223
229
247
244
93,679
108,841
3,421
171,621
4,155
50,414
4,631
9,409
5,884
6,112
4,534
5,290
5,2904,5346,1125,8849,4094,63150,4144,155171,6213,421108,84193,67924424722922361,11810,99910,915132,20355,82040,60210,58710,50610,50616,76739,20453,15571,01098,730111,540122,009131,720127,974138,310139,518144,269000000
       Long-term Assets Other 
0
0
8,055
0
10,958
11,788
8,850
8,962
9,055
9,093
9,270
8,912
9,016
9,247
8,369
9,202
9,499
10,026
9,698
10,062
10,420
8,348
7,565
8,337
8,959
11,213
11,444
10,674
8,934
6,103
5,505
11,201
6,689
7,179
7,991
9,005
6,573
7,012
7,354
6,744
6,425
6,024
3,650
3,6506,0246,4256,7447,3547,0126,5739,0057,9917,1796,68911,2015,5056,1038,93410,67411,44411,2138,9598,3377,5658,34810,42010,0629,69810,0269,4999,2028,3699,2479,0168,9129,2709,0939,0558,9628,85011,78810,95808,05500
> Total Liabilities 
143,404
0
189,349
0
232,792
234,734
242,852
231,653
268,509
262,692
273,749
266,312
286,752
288,597
294,443
290,784
293,269
304,123
316,200
348,822
355,117
365,059
352,128
303,903
266,764
280,246
321,991
346,748
392,540
341,084
385,391
397,028
528,767
505,450
544,708
567,919
563,042
562,564
611,567
567,429
575,434
575,628
585,728
585,728575,628575,434567,429611,567562,564563,042567,919544,708505,450528,767397,028385,391341,084392,540346,748321,991280,246266,764303,903352,128365,059355,117348,822316,200304,123293,269290,784294,443288,597286,752266,312273,749262,692268,509231,653242,852234,734232,7920189,3490143,404
   > Total Current Liabilities 
23,678
0
37,479
0
48,947
53,283
62,754
53,957
63,502
58,988
67,181
58,303
66,443
61,744
65,125
60,113
59,774
68,498
77,258
83,342
90,559
100,426
89,033
93,920
82,812
87,286
102,745
66,101
77,571
118,348
163,187
167,047
232,764
209,316
225,497
255,374
240,340
251,994
273,562
254,746
194,072
209,415
217,668
217,668209,415194,072254,746273,562251,994240,340255,374225,497209,316232,764167,047163,187118,34877,57166,101102,74587,28682,81293,92089,033100,42690,55983,34277,25868,49859,77460,11365,12561,74466,44358,30367,18158,98863,50253,95762,75453,28348,947037,479023,678
       Short-term Debt 
0
0
403
0
403
403
403
38,970
42,997
37,632
43,170
39,872
43,380
44,780
45,034
41,536
41,121
43,787
57,323
55,306
40,737
42,967
60,586
11,766
12,071
12,149
12,351
12,396
12,279
12,311
12,330
12,480
10,741
10,846
10,955
10,978
10,984
11,504
10,292
9,927
11,011
11,884
14,117
14,11711,88411,0119,92710,29211,50410,98410,97810,95510,84610,74112,48012,33012,31112,27912,39612,35112,14912,07111,76660,58642,96740,73755,30657,32343,78741,12141,53645,03444,78043,38039,87243,17037,63242,99738,970403403403040300
       Short Long Term Debt 
0
0
0
0
0
0
113,283
0
0
0
112,127
0
0
0
112,206
112,688
113,735
114,292
115,007
115,444
114,454
0
0
436
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000043600114,454115,444115,007114,292113,735112,688112,206000112,127000113,283000000
       Accounts payable 
3,107
0
1,066
0
1,256
2,895
4,551
2,433
3,915
4,234
6,521
1,543
3,474
2,039
6,223
2,950
3,261
6,407
5,509
3,549
3,222
10,131
9,139
3,772
4,060
4,055
6,088
2,865
5,015
7,553
24,789
24,061
48,988
23,868
26,097
36,353
29,360
19,323
30,758
71,282
12,802
19,220
17,960
17,96019,22012,80271,28230,75819,32329,36036,35326,09723,86848,98824,06124,7897,5535,0152,8656,0884,0554,0603,7729,13910,1313,2223,5495,5096,4073,2612,9506,2232,0393,4741,5436,5214,2343,9152,4334,5512,8951,25601,06603,107
       Other Current Liabilities 
19,653
0
30,269
0
37,462
40,446
48,582
3,496
3,243
4,142
4,762
4,166
4,562
6,968
5,880
7,643
7,413
10,330
6,458
7,553
8,755
9,631
5,537
66,278
66,545
70,825
83,816
42,309
50,464
90,572
119,521
103,802
134,008
141,011
172,588
200,540
191,697
213,806
219,383
157,042
162,769
170,986
172,851
172,851170,986162,769157,042219,383213,806191,697200,540172,588141,011134,008103,802119,52190,57250,46442,30983,81670,82566,54566,2785,5379,6318,7557,5536,45810,3307,4137,6435,8806,9684,5624,1664,7624,1423,2433,49648,58240,44637,462030,269019,653
   > Long-term Liabilities 
0
0
151,870
0
183,845
181,451
180,098
177,696
205,007
203,704
206,568
208,009
220,309
226,853
229,318
230,671
233,495
235,625
238,942
265,480
264,558
264,633
263,095
209,983
183,952
192,960
219,246
280,647
314,969
222,736
222,204
229,981
296,003
296,134
319,211
312,545
322,702
310,570
338,005
312,683
381,362
366,213
368,060
368,060366,213381,362312,683338,005310,570322,702312,545319,211296,134296,003229,981222,204222,736314,969280,647219,246192,960183,952209,983263,095264,633264,558265,480238,942235,625233,495230,671229,318226,853220,309208,009206,568203,704205,007177,696180,098181,451183,8450151,87000
       Long term Debt Total 
0
0
0
0
0
0
0
96,873
96,929
96,990
97,042
97,077
97,395
97,377
97,352
97,536
97,451
0
0
0
0
0
113,955
64,806
61,968
58,211
55,531
52,121
0
0
0
0
0
0
0
0
0
0
0
0
71,408
0
0
0071,40800000000000052,12155,53158,21161,96864,806113,9550000097,45197,53697,35297,37797,39597,07797,04296,99096,92996,8730000000
       Capital Lease Obligations Min Short Term Debt
0
0
-403
0
-403
-403
-403
-38,970
-42,997
-37,632
-43,170
-39,872
-43,380
-44,780
-45,034
-41,536
-41,121
-43,787
-57,323
-55,306
-40,737
-42,967
-60,586
46,818
43,780
40,713
37,610
34,545
32,158
29,825
26,244
25,547
94,202
91,483
88,779
85,948
83,080
81,091
79,593
76,885
73,813
70,035
66,497
66,49770,03573,81376,88579,59381,09183,08085,94888,77991,48394,20225,54726,24429,82532,15834,54537,61040,71343,78046,818-60,586-42,967-40,737-55,306-57,323-43,787-41,121-41,536-45,034-44,780-43,380-39,872-43,170-37,632-42,997-38,970-403-403-4030-40300
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21,480
0
0
0021,4800000000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
15,473
15,888
16,180
19,692
21,023
20,506
20,501
21,045
20,992
22,529
120,982
123,054
124,005
261,208
261,436
260,057
209,983
183,952
192,960
219,246
280,647
314,969
222,736
222,204
229,981
20,746
296,134
43,631
312,545
34,271
310,570
23,357
312,683
22,326
70,306
72,034
72,03470,30622,326312,68323,357310,57034,271312,54543,631296,13420,746229,981222,204222,736314,969280,647219,246192,960183,952209,983260,057261,436261,208124,005123,054120,98222,52920,99221,04520,50120,50621,02319,69216,18015,88815,4730000000
       Deferred Long Term Liability 
0
0
0
0
0
0
66,119
65,350
92,190
90,534
85,132
89,909
102,408
108,975
110,921
112,143
113,515
114,643
115,888
141,475
3,350
3,197
3,038
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000003,0383,1973,350141,475115,888114,643113,515112,143110,921108,975102,40889,90985,13290,53492,19065,35066,119000000
> Total Stockholder Equity
94,484
0
79,728
0
111,990
81,774
221,405
184,616
253,615
217,284
177,554
156,952
193,106
178,345
155,838
131,701
230,098
571,498
563,179
499,518
495,531
471,311
509,199
489,223
629,031
594,447
516,135
458,358
395,872
451,660
422,178
371,002
260,580
325,792
209,146
158,048
103,780
26,306
-21,447
-48,852
-102,274
-157,169
-204,166
-204,166-157,169-102,274-48,852-21,44726,306103,780158,048209,146325,792260,580371,002422,178451,660395,872458,358516,135594,447629,031489,223509,199471,311495,531499,518563,179571,498230,098131,701155,838178,345193,106156,952177,554217,284253,615184,616221,40581,774111,990079,728094,484
   Common Stock
132
0
132
0
337
135
590
593
604
612
620
624
627
631
637
644
710
818
825
834
842
848
854
861
868
872
877
889
902
909
914
921
926
927
929
933
937
939
942
966
982
983
988
98898398296694293993793392992792692191490990288987787286886185484884283482581871064463763162762462061260459359013533701320132
   Retained Earnings Total Equity00-1,722,073-1,634,3930-1,491,513-1,399,863-1,327,239-1,264,034-1,129,956-1,179,754-1,045,766-974,011-915,377-948,381-863,068-784,720-686,597-637,158-753,161-715,827-736,780-694,224-670,803-595,945-573,823-536,086-502,903-469,742-435,740-411,586-435,903-408,062-356,693-311,595-368,6500000000
   Accumulated Other Comprehensive Income 
0
0
-3,508
0
-4,133
-3,177
-3,149
-738
-623
-1,614
-1,651
-1,704
-1,024
-1,333
-960
-1,020
-1,387
-1,609
-1,795
-3,622
-2,611
-2,570
-2,281
-937
-462
-224
-747
1,183
-1,561
-4,256
-4,499
-4,624
-4,567
-4,158
-4,163
-6,505
-6,930
-7,346
-5,720
-4,570
-6,250
-6,923
-6,875
-6,875-6,923-6,250-4,570-5,720-7,346-6,930-6,505-4,163-4,158-4,567-4,624-4,499-4,256-1,5611,183-747-224-462-937-2,281-2,570-2,611-3,622-1,795-1,609-1,387-1,020-960-1,333-1,024-1,704-1,651-1,614-623-738-3,149-3,177-4,1330-3,50800
   Capital Surplus 
0
0
0
0
0
0
0
553,411
565,229
574,979
586,647
593,935
605,089
614,787
625,903
634,980
766,861
1,146,112
1,160,094
1,173,109
1,191,524
1,209,813
1,226,453
1,242,460
1,265,783
1,280,396
1,300,725
1,319,354
1,344,912
1,370,384
1,399,774
1,420,471
1,443,975
1,458,979
1,476,414
1,490,859
1,509,636
1,524,226
0
1,589,145
1,625,067
0
0
001,625,0671,589,14501,524,2261,509,6361,490,8591,476,4141,458,9791,443,9751,420,4711,399,7741,370,3841,344,9121,319,3541,300,7251,280,3961,265,7831,242,4601,226,4531,209,8131,191,5241,173,1091,160,0941,146,112766,861634,980625,903614,787605,089593,935586,647574,979565,229553,4110000000
   Treasury Stock0000000000000000000000000000000-176,223-196,825-236,555-272,886-203,8870000000
   Other Stockholders Equity 
0
0
41,134
0
43,225
51,790
546,247
553,411
565,229
574,979
586,647
593,935
605,089
614,787
625,903
634,980
766,861
1,146,112
1,160,094
1,173,109
1,191,524
1,209,813
1,226,453
1,242,460
1,265,783
1,280,396
1,300,725
1,319,354
1,344,912
1,370,384
1,399,774
1,420,471
1,443,975
1,458,979
213,309
1,490,859
1,509,636
1,524,226
1,541,019
1,589,145
1,625,067
1,634,459
1,643,641
1,643,6411,634,4591,625,0671,589,1451,541,0191,524,2261,509,6361,490,859213,3091,458,9791,443,9751,420,4711,399,7741,370,3841,344,9121,319,3541,300,7251,280,3961,265,7831,242,4601,226,4531,209,8131,191,5241,173,1091,160,0941,146,112766,861634,980625,903614,787605,089593,935586,647574,979565,229553,411546,24751,79043,225041,13400



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue147,752
Cost of Revenue-18,848
Gross Profit128,904128,904
 
Operating Income (+$)
Gross Profit128,904
Operating Expense-398,113
Operating Income-269,209-269,209
 
Operating Expense (+$)
Research Development282,861
Selling General Administrative124,995
Selling And Marketing Expenses0
Operating Expense398,113407,856
 
Net Interest Income (+$)
Interest Income8,908
Interest Expense-15,532
Other Finance Cost-3,949
Net Interest Income-2,675
 
Pretax Income (+$)
Operating Income-269,209
Net Interest Income-2,675
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-286,867-251,551
EBIT - interestExpense = -284,741
-284,229
-268,700
Interest Expense15,532
Earnings Before Interest and Taxes (EBIT)-269,209-271,335
Earnings Before Interest and Taxes (EBITDA)-259,279
 
After tax Income (+$)
Income Before Tax-286,867
Tax Provision-31
Net Income From Continuing Ops-294,175-286,898
Net Income-284,232
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses416,961
Total Other Income/Expenses Net-17,6582,675
 

Technical Analysis of Fibrogen
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Fibrogen. The general trend of Fibrogen is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Fibrogen's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of FibroGen Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1.1801 < 1.69 < 2.8.

The bearish price targets are: 0.9992 > 0.9478 > 0.91.

Tweet this
FibroGen Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of FibroGen Inc. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

FibroGen Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of FibroGen Inc. The current macd is -0.25548235.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Fibrogen price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Fibrogen. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Fibrogen price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
FibroGen Inc Daily Moving Average Convergence/Divergence (MACD) ChartFibroGen Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of FibroGen Inc. The current adx is 42.00.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Fibrogen shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
FibroGen Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of FibroGen Inc. The current sar is 1.58939909.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
FibroGen Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of FibroGen Inc. The current rsi is 28.38. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 2/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending up: The RSI is trending up. +1
FibroGen Inc Daily Relative Strength Index (RSI) ChartFibroGen Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of FibroGen Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Fibrogen price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
FibroGen Inc Daily Stochastic Oscillator ChartFibroGen Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of FibroGen Inc. The current cci is -105.48308982.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
FibroGen Inc Daily Commodity Channel Index (CCI) ChartFibroGen Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of FibroGen Inc. The current cmo is -57.92395933.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
FibroGen Inc Daily Chande Momentum Oscillator (CMO) ChartFibroGen Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of FibroGen Inc. The current willr is -84.92838129.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
FibroGen Inc Daily Williams %R ChartFibroGen Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of FibroGen Inc.

FibroGen Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of FibroGen Inc. The current atr is 0.20188543.

FibroGen Inc Daily Average True Range (ATR) ChartFibroGen Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of FibroGen Inc. The current obv is -81,663,613.

FibroGen Inc Daily On-Balance Volume (OBV) ChartFibroGen Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of FibroGen Inc. The current mfi is 20.97.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
FibroGen Inc Daily Money Flow Index (MFI) ChartFibroGen Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for FibroGen Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-01ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-08MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-09ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

FibroGen Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of FibroGen Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5028.381
Ma 20Greater thanMa 501.459
Ma 50Greater thanMa 1001.824
Ma 100Greater thanMa 2001.456
OpenGreater thanClose0.950
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Fibrogen with someone you think should read this too:
  • Are you bullish or bearish on Fibrogen? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Fibrogen? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about FibroGen Inc

I send you an email if I find something interesting about FibroGen Inc.


Comments

How you think about this?

Leave a comment

Stay informed about FibroGen Inc.

Receive notifications about FibroGen Inc in your mailbox!